0001225208-12-016966.txt : 20120801 0001225208-12-016966.hdr.sgml : 20120801 20120801135722 ACCESSION NUMBER: 0001225208-12-016966 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120730 FILED AS OF DATE: 20120801 DATE AS OF CHANGE: 20120801 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Baxter Allan CENTRAL INDEX KEY: 0001519029 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14169 FILM NUMBER: 12999452 MAIL ADDRESS: STREET 1: CHALKLEYS BARN STREET 2: CHURCH LANE GRAVELEY CITY: HERTS STATE: X0 ZIP: SG47LR ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: HUMAN GENOME SCIENCES INC CENTRAL INDEX KEY: 0000901219 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 223178468 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 14200 SHADY GROVE ROAD CITY: ROCKVILLE STATE: MD ZIP: 20850-3338 BUSINESS PHONE: 3013098504 MAIL ADDRESS: STREET 1: 14200 SHADY GROVE ROAD CITY: ROCKVILLE STATE: MD ZIP: 20850 4 1 doc4.xml X0306 4 2012-07-30 1 0000901219 HUMAN GENOME SCIENCES INC HGSI 0001519029 Baxter Allan 14200 SHADY GROVE ROAD ROCKVILLE MD 20850 1 Common Stock 2012-07-30 4 D 0 2500.0000 14.2500 D 0.0000 D Non-Employee Director Stock Option - Right to Buy 14.2300 2012-07-30 4 D 0 16000.0000 14.2500 D 2022-05-17 Common Stock 16000.0000 0.0000 D Each restricted stock unit represents a contingent right to receive one (1) share of Human Genome Sciences, Inc. common stock. These restricted stock units were cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $35,625.00, ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc. These restricted stock units vested automatically upon consummation of the tender offer on July 30, 2012. This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $320.00, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc. These options vested automatically upon consummation of the tender offer on July 30, 2012. /s/James H. Davis (Power of Attorney) on behalf of 2012-08-01